Rongxi Wang

state key laboratory of complex severe and rare diseases

H指数:11

被引数:345

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

68Ga-FAPI PET/CT for assessing fibroblast activation and disease activity in primary Sjögren’s disease: a prospective case-control study

^{68}Ga-FAPI PET/CT在评估原发性舍格伦综合征中成纤维细胞活化和疾病活动度中的应用：一项前瞻性病例对照研究

Rheumatology

IF4.4

2026-08-280

PRE

Right parotid gland oncocytic carcinoma on [18F]FDG and [68Ga]Ga-FAPI-04 PET/CT

右侧腮腺嗜酸细胞癌在[18F]FDG和[68Ga]Ga-FAPI-04 PET/CT中的表现

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2026-08-220

PRE

[68Ga]Ga-P16-093 PET/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [68Ga]Ga-PSMA-11

[68Ga]Ga-P16-093 PET/CT在 newly diagnosed 前列腺癌中的应用：组织病理学验证与[68Ga]Ga-PSMA-11的对比

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2025-12-100

PRE

68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study

EJNMMI RESEARCH

IF3

2025-01-170

OAAI

Preclinical and First-in-Human Study of a Compact Radionuclide Labeled Self-Assembly Nanomedicine for Chemo-Radio-Theranostics of Cancer

癌症的化疗-放疗-诊疗一体化用的一种紧凑型放射性核素标记的自组装纳米药物的体外和首次人体研究

ACS NANO

IF16

2025-01-130

PRE

Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68Ga-HBED-CC-Exendin-4 in Localizing Insulinoma

CLINICAL NUCLEAR MEDICINE

IF9.6

2024-11-080

PRE

Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin avb3-positive tumors: A first-in-human study

安全性、药代动力学和剂量测定：177Lu-AB-3PRGD2在整合素avb3阳性晚期肿瘤患者中的首次人体研究

ACTA PHARMACEUTICA SINICA B

IF14.6

2024-11-010

OAAI

Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2024-06-271

PRE

Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2024-04-253

PRE

Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2024-02-206

PRE

Lower-grade gliomas surgery guided by GRPR-targeting PET/NIR dual-modality image probe: a prospective and single-arm clinical trial

THERANOSTICS

IF13.3

2024-01-012

OAAI

68Ga-FAPI-04 PET/CT in Assessment of Fibroblast Activation in Keloids: A Prospective Pilot Study

68Ga-FAPI-04 PET/CT评估瘢痕疙瘩成纤维细胞活化: 一项前瞻性先导研究

CLINICAL NUCLEAR MEDICINE

IF9.6

2023-11-242

PRE

A prospective head-to-head comparison of -[68Ga]Ga-P16-093 and -[68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

原发性前列腺癌患者-[68Ga]Ga-P16-093和-[68Ga]Ga-PSMA-11 PET/CT的前瞻性头-头比较

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2023-05-269

OAAI

The value of 18F-FDG PET/CT in the systemic evaluation of patients with Rosai-Dorfman disease: a retrospective study and literature review

ORPHANET JOURNAL OF RARE DISEASES

IF3.5

2023-05-133

OAAI

Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer 99mTc-HP-Ark2: a pilot study

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2023-01-115

OAAI

Dual targeting PET tracer [68Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study

THERANOSTICS

IF13.3

2023-01-0116

OAAI

A Single-Arm, Low-Dose, Prospective Study of 177 Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2022-11-0315

A prospective head-to-head comparison of 68Ga-NOTA-3P-TATE-RGD and 68Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2022-06-034

PRE

Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors

THERANOSTICS

IF13.3

2022-01-0111

OAAI

Portal Biliopathy and Cavernous Transformation of the Portal Vein Revealed by 68Ga-FAPI PET/CT

CLINICAL NUCLEAR MEDICINE

IF9.6

2021-07-154

PREAI

Rongxi Wang

个人简介

教育背景

工作经历

荣誉奖项

研究方向